The Multiple Myeloma Research Consortium (MMRC) is collaborating with Sunesis Pharmaceuticals to further evaluate the company’s Phase I compound. SNS-032 is currently being tested in patients with multiple myeloma and chronic lymphocytic leukemia.
The MMRC will investigate the preclinical activity of SNS-032 in multiple myeloma-relevant models and in primary disease tissue. Data from these studies, according to Sunesis, will help identify relevant mechanism-based biomarkers of patient response. The company says that such information may guide rational combination strategies in planned clinical trials of SNS-032 in multiple myeloma.
SNS-032 is a potent, selective inhibitor of cyclin-dependent kinases 2, 7 and 9 that suppresses both cell cycle progression and transcription. It has reportedly been shown in preclinical and clinical studies to deplete cells of key survival factors including myeloid cell leukemia sequence 1.